In 2017, Chong et al. [22] published the case of a patient with progressing DLBCL who was first treated with anti-CD19 CAR-modified T-cells and subsequently with an anti-PD-1 antibody. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.